Company Description
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual‑targeting CD19/CD20 CAR T‑cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi‑R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity.
Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jun 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 300 |
| CEO | Lynn Seely |
Contact Details
Address: 201 Haskins Way, Suite 101 South San Francisco, California 94080 United States | |
| Phone | 650 695 0677 |
| Website | lyell.com |
Stock Details
| Ticker Symbol | LYEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1806952 |
| CUSIP Number | 55083R203 |
| ISIN Number | US55083R2031 |
| Employer ID | 83-3006753 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lynn Seely M.D., Ph.D. | Principal Executive Officer, President, Chief Executive Officer and Director |
| Dr. Richard D. Klausner M.D. | Founder and Executive Chairman |
| Stephen J. Hill | Chief Operating Officer |
| Prof. Stanley R. Riddell M.D. | Founder and Scientific Advisor |
| Dr. Crystal L. Mackall M.D. | Founder and Scientific Advisor |
| Smital Shah M.B.A. | Principal Financial Officer, Chief Financial Officer and Chief Business Officer |
| Nellie Dillery | Director of Accounting |
| Dr. Gary K. Lee Ph.D. | Chief Scientific Officer |
| Mark A. Meltz J.D. | General Counsel and Corporate Secretary |
| Ann Tomlin | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2026 | 10-K | Annual Report |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |
| Dec 18, 2025 | 424B5 | Filing |
| Dec 15, 2025 | EFFECT | Notice of Effectiveness |
| Dec 8, 2025 | 8-K | Current Report |
| Dec 5, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 5, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |